Please Wait...

Mary Karpa

Translation skills

Main profile

Mary Karpa
Corporate Public Relations and Social Media Lead

Mary is a Marketing Communication and PR professional with more than 15 years of experience within the pharma, healthcare and engineering sectors.  Working hand-in-hand with subject matter experts, she digs below the surface, bringing understanding to complex thoughts and processes. Mary has a bachelor’s degree in Telecommunications from Penn State University.

Blogs

Reducing risk to the clinical supply chain through advanced optimization techniques

Congressman Meehan and Bioclinica CEO John Hubbard at recent visit to Bioclinica's Audubon offices

Bioclinica was honored to host Congressman Patrick Meehan representing the 7th Congressional District in Pennsylvania in a visit to our Audubon, Pennsylvania offices on August 28. Congressman Meehan met with Bioclinica senior leadership, including our CEO Dr. John Hubbard...

What's behind slow site activation?

Sean Stanton of Bioclinica Research provides meaningful insights on study site activation in his latest article, 'Improving Site Activation: Three-Fold Solution' published in ICT's August 2017 issue.

Elizabeth Thiele

Finding patients to participate in clinical trials and keeping them engaged for the duration are two of the greatest challenges in the clinical development process.

Bioclinica on Worldwide Business with Kathy Ireland

Catch a candid discussion with Bioclinica experts as they discuss clinical trials and ways to simplify the clinical development process in a recent episode of Worldwide Business with Kathy Ireland®!

Each week the Fox Business Network sponsored program explores the real-world insights of corporate executives from around the globe.

LEARN MORE OR SPEAK WITH OUR EXPERTS

CONTACT US
Leader in Clinical Trial
Management Solutions

Successful clinical trials require the ability to see key details and uncover hidden insights. Bioclinica utilizes science and technology to bring clarity to clinical trials, helping companies to develop new life-improving therapies more efficiently and safely.

RT @endpts: #FDA revises draft guidance on #raredisease drug R&D https://t.co/KaNVw54MDE by @ZacharyBrennan via @RAPSorg
Bioclinica (12 hours ago)
RT @PrimeVigilance: News and Press Release - Source @EMA_News now available monthly meeting highlights from #Pharmacovigilance #RiskAssessm…
Bioclinica (12 hours ago)
RT @FDA_Drug_Info: New #FDA Draft Guidance for Industry on Rare Diseases – Common Issues in Drug Development: https://t.co/yxaGyMB7hY. http…
Bioclinica (12 hours ago)
Looking to exercise DDDM in clinical trials? Get tips on obtaining, distilling and presenting data in our new white… https://t.co/NkGrS9JnG8
Bioclinica (14 hours ago)
Is your clinical study supply chain management solution increasing the risk of stock out? Ehsan Ramezani gives pers… https://t.co/YCfP3wCvK6
Bioclinica (Yesterday)
Bioclinica's Kate Adamczuk is presenting at #HAI2019 today! Details on this and other scientific findings at HAI… https://t.co/wDQr6ldfcS
Bioclinica (Yesterday)

Latest Blogs:

Nonalcoholic steatohepatitis (NASH) development programs
Dr. Joby John
Transformational Trends in Investigator Site Payments
Clinical Supply Chain Success: Leveraging Technology
Blood pressure monitor
Prescription box
Latin America: Benefit from the Right Partner